MSC-EVs represent a promising and multifaceted therapeutic strategy for bone regeneration in peri-implantitis, simultaneously targeting inflammation, bone resorption, and osteogenesis. While robust preclinical evidence supports their role in halting bone loss and promoting structured regeneration, successful clinical translation requires further standardization, optimization of delivery, and validation in human trials.
Bonilla et al. (Wed,) studied this question.